CONMED Q3 2026 earnings

CNMD · 2026-10-28 16:08 AMC ET · 8-K on SEC

Adjusted diluted EPS declined 3.2% year-over-year despite organic constant currency net sales growth of 6.7% and a 613.7% increase in GAAP EPS driven by a tax benefit.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$335.6M-0.7%-2.3%Ex. 99.1, Highlights
EPS (GAAP)$0.66+613.7%-14.3%Ex. 99.1, Highlights
EPS (adjusted)$1.04-3.2%-24.6%Ex. 99.1, Highlights
Net income$19.8M+593.1%-14.3%Ex. 99.1, Income Statement
Adj. EBITDA$31.4M+21.3%-39.2%Ex. 99.1, Adjusted Net Income
Adj. EBITDA margin15.4%+1.3 pp-2.8 ppEx. 99.1, Adjusted Net Income

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 56.4% (57.5% prior, -1.1 pp)
  • Operating expenses $136.4M (+3.0% YoY)
  • One-offs in the quarter Gain on early extinguishment of debt, net $2.8M; Gain on sale of product offering $213K; Termination of distribution agreement $162K; EU medical device regulations $1.9M; Operational optimization costs $3.1M
  • Effective tax rate 23.9% (prior-year 33.1%, year-to-date 25.1%)
  • Non-GAAP bridge Adds back operational optimization costs, EU medical device regulations, contingent consideration fair value adjustments, termination of distribution agreement, gain on sale of product offering, amortization, and stock-based compensation to get from GAAP to adjusted.

KPIs

MetricActualPrior quarterPrior yearChange
Organic constant currency net sales growth6.7%6.0%N/A+0.7 pp
International sales growth (reported)13.1%10.8%N/A+2.3 pp
Domestic sales growth (reported)-11.0%-8.0%N/A-3.0 pp

Guidance

MetricGuidePrior guideChange
Net Sales (GAAP)$1,360M - $1,366M$1,358M - $1,373MHigh - $2M, Low - $7M
Adjusted Diluted EPS$4.54 - $4.61$4.48 - $4.60High +$0.06, Low +$0.01

What drove it

  • Revenue story Organic constant currency net sales increased 6.7% driven by balanced contributions from Orthopedic and General Surgery product lines, with International sales up 13.1% and Domestic sales down 11.0%.
  • EPS story GAAP EPS increased 613.7% due to a lower effective tax rate (23.9% vs 33.1% prior year) and lower interest expense; Adjusted EPS decreased 3.2% due to higher operational optimization costs and a larger share count.
  • One-off check Gain on early extinguishment of debt, net $2.8M; Gain on sale of product offering $213K; Termination of distribution agreement $162K; EU medical device regulations $1.9M; Operational optimization costs $3.1M.

The good

  • Organic constant currency net sales growth of 6.7%
  • International sales growth of 13.1% reported
  • Adjusted EBITDA margin of 15.4%

The bad

  • Domestic sales decreased 11.0% reported
  • Adjusted diluted EPS decreased 3.2% year-over-year
  • Adjusted EBITDA decreased 39.2% quarter-over-quarter

The ugly

  • none

Open questions

  • What specific factors drove the 39.2% quarter-over-quarter decline in Adjusted EBITDA?
  • What caused the 24.6% quarter-over-quarter decline in Adjusted diluted EPS?
Full release

Earnings: CNMD — filed 2026-10-28

CONMED Corp (CNMD) · Form 8-K, Item 2.02 · Filed · SEC filing

NEWS RELEASE

CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

Largo, Florida, October 28, 2026 – CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year ending 2026.

Third Quarter 2026 Highlights

(1)

• Sales of $335.6 million decreased 0.7% year-over-year as reported and decreased 0.8% on a constant currency

Financial statements

Income Statement

Twelve Months Ending December 31, 2026 (in millions)

Twelve Months Ending December 31, 2026 – Updated Financial Guidance – HighTwelve Months Ending December 31, 2026 – Updated Financial Guidance – LowTwelve Months Ending December 31, 2026 – Prior Financial Guidance(5) – HighTwelve Months Ending December 31, 2026 – Prior Financial Guidance(5)
Net Sales (GAAP)1,3601,3661,3581,373
Net Sales Growth, as reported-1.1-0.6-1.2-0.1
Estimated impact of foreign currency exchange rate fluctuations-0.7-0.7-0.5-0.5
Net Sales Growth, Constant Currency-1.7-1.3-1.7-0.7
Estimated impact of strategic product offering exits(3)6.76.86.76.7
Net Sales Growth, Organic Constant Currency55.556
Adjusted Diluted EPS(4)4.544.614.484.6
Percentage Change-1.20.4-2.40.2

Income Statement (in thousands except per share amounts, unaudited)

Consolidated Condensed Statements of Income – Three Months Ended – September 30, – 2026Consolidated Condensed Statements of Income – Three Months Ended – September 30, – 2025Consolidated Condensed Statements of Income – Nine Months Ended – September 30, – 2026Consolidated Condensed Statements of Income – Nine Months Ended – September 30, – 2025
Net sales335,557337,926996,0901,001,526
Cost of sales146,409171,807426,038469,336
Gross profit189,148166,119570,052532,190
% of sales56.449.257.253.1
Selling & administrative expense136,416140,339423,667425,207
Research & development expense15,58813,90147,42140,985
Income from operations37,14411,87998,96465,998
% of sales11.13.59.96.6
Interest expense11,1357,60626,07823,716
Other (income) / expense-2,825418
Income before income taxes26,0094,27375,71141,864
Provision for income taxes6,2131,41419,01611,548
Net income19,7962,85956,69530,316
Basic EPS0.660.091.880.98
Diluted EPS0.660.091.870.97
Basic shares29,92630,95530,17831,027
Diluted shares30,12531,05030,25331,145

Income Statement

(2) Organic constant currency revenue excludes the sales of gastroenterology ("GI") product offerings for the nine months ended September 30, 2026 and 2025. (in thousands, except per share amounts, unaudited)

Three Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Gross ProfitGross ProfitThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Selling & Administrative ExpenseSelling & Administrative ExpenseThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Research & Development ExpenseResearch & Development ExpenseThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Operating IncomeOperating IncomeThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Interest ExpenseInterest ExpenseThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Tax ExpenseTax ExpenseThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Effective Tax RateEffective Tax RateThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Net IncomeNet IncomeThree Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Diluted EPSDiluted EPS
As reported189,148136,41615,58837,14411,1356,21323.919,7960.66
% of sales56.440.74.611.1
Operational optimization costs(1)97-3,1323,2296592,570
EU medical device regulations(2)-1,8571,8573791,478
Contingent consideration fair value adjustments(3)-605605124481
Termination of distribution agreement(4)16216233129
Gain on sale of product offering(5)213-213-43-170
189,407132,89213,73142,78411,1357,36524,284
Adjusted gross profit %56.4
Amortization(6)1,500-7,2478,747-6112,2707,088
As adjusted125,64513,73151,53110,5249,63523.531,3721.04
% of sales37.44.115.4
Three Months Ended September 30, 2025As reported166,119140,33913,90111,8797,6061,41433.12,8590.09
Three Months Ended September 30, 2025% of sales49.241.54.13.5
Three Months Ended September 30, 2025Operational optimization costs(1)3,729-5,5169,2452,2916,954
Three Months Ended September 30, 2025Contingent consideration fair value adjustments(3)-1,3411,3413321,009
Three Months Ended September 30, 2025Product rationalization costs(7)19,65319,6534,87014,783
Three Months Ended September 30, 2025Legal matters(8)-31931979240
Three Months Ended September 30, 2025189,501133,16313,90142,4377,6068,98625,845

Income Statement

(2) Organic constant currency revenue excludes the sales of gastroenterology ("GI") product offerings for the nine months ended September 30, 2026 and 2025. (in thousands, except per share amounts, unaudited)

Nine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Gross ProfitGross ProfitNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Selling & Administrative ExpenseSelling & Administrative ExpenseNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Research & Development ExpenseResearch & Development ExpenseNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Operating IncomeOperating IncomeNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Interest ExpenseInterest ExpenseOther (Income) / ExpenseNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Other (Income) / ExpenseOther (Income) / ExpenseNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Tax ExpenseTax ExpenseNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Effective Tax RateEffective Tax RateNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Net IncomeNet IncomeNine Months Ended September 30, 2026 – Reconciliation of Reported Net Income to Adjusted Net Income – Diluted EPSDiluted EPS
As reported570,052423,66747,42198,96426,078-2,82519,01625.156,6951.87
% of sales57.242.54.89.9
Operational optimization costs(1)476-17,73118,2074,11214,095
Product rationalization costs(2)6,9116,9111,6145,297
Loss on sale of product offering(3)-4,4254,4251,0333,392
EU medical device regulations(4)-4,1074,1078983,209
Executive transition costs(5)-3,3423,3427612,581
Contingent consideration fair value adjustments(6)-1,2151,215262953
Gain on early extinguishment of debt, net(7)2,825-660-2,165
Termination of distribution agreement(8)-1,702-1,702-391-1,311
Gain on sale of product offering(9)6,066-6,066-1,388-4,678
575,737403,02043,314129,40326,07825,25778,068
Adjusted gross profit %57.8
Amortization(10)4,500-21,74526,245-2,9407,07622,109
As adjusted381,27543,314155,64823,13832,33324.4100,1773.31
% of sales38.34.315.6
Nine Months Ended September 30, 2025As reported532,190425,20740,98565,99823,71641811,54827.630,3160.97
Nine Months Ended September 30, 2025% of sales53.142.54.16.6
Nine Months Ended September 30, 2025Operational optimization costs(1)12,262-8,45620,7184,04516,673
Nine Months Ended September 30, 2025Product rationalization costs(2)19,65319,6534,87014,783
Nine Months Ended September 30, 2025Executive transition costs(5)-12,16512,1652,8129,353
Nine Months Ended September 30, 2025Contingent consideration fair value adjustments(6)-3,5043,5041,0462,458
Nine Months Ended September 30, 2025Legal matters(11)-2,5482,5484532,095
Nine Months Ended September 30, 2025Loss on early extinguishment of debt, net(7)-41847371
Nine Months Ended September 30, 2025Gain on sale of product offering(9)354-354-82-272
Nine Months Ended September 30, 2025564,105398,88840,985124,23223,71624,73975,777
Nine Months Ended September 30, 2025Adjusted gross profit %56.3
Nine Months Ended September 30, 2025Amortization(10)4,500-21,59726,097-4,1077,33522,869
Nine Months Ended September 30, 2025As adjusted377,29140,985150,32919,60932,07424.598,6463.17

Income Statement

(2) Organic constant currency revenue excludes the sales of gastroenterology ("GI") product offerings for the nine months ended September 30, 2026 and 2025. (in thousands)

Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA – Three Months Ended – September 30, – 2026Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA – Three Months Ended – September 30, – 2025Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA – Nine Months Ended – September 30, – 2026Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA – Nine Months Ended – September 30, – 2025
Net income19,7962,85956,69530,316
Provision for income taxes6,2131,41419,01611,548
Interest expense11,1357,60626,07823,716
Depreciation3,9814,37612,23413,077
Amortization15,20214,23144,83242,354
EBITDA56,32730,486158,855121,011
Stock based compensation5,9114,58515,92515,869
Operational optimization costs3,2299,24518,20720,718
EU medical device regulations1,8574,107
Contingent consideration fair value adjustments6051,3411,2153,504
Termination of distribution agreement162-1,702
Gain on sale of product offering-213-6,066-354
Product rationalization costs19,6536,91119,653
Loss on sale of product offering4,425
Executive transition costs3,34212,165
(Gain) / loss on early extinguishment of debt, net-2,825418
Legal matters3192,548
Adjusted EBITDA67,87865,629202,394195,532
EBITDA MarginEBITDA16.8915.912.1
EBITDA MarginAdjusted EBITDA20.219.420.319.5

(2) basis.

• Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.7% on an organic constant currency

(2) (3) basis.

• Domestic sales decreased 11.0% as reported and increased 0.8% on an organic

(2)(3) basis.

• International sales increased 13.1% as reported, increased 12.8% on a constant currency

(2) basis, and increased 13.8% on an organic constant currency

(2)(3) basis.

• Diluted earnings per share (GAAP) were $0.66, up 613.7%.

• Adjusted diluted earnings per share

(2) were $1.04, down 3.2%.

Third Quarter 2026 Operational Announcements

• On July 22, 2026, the Company announced the AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform.

"Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflecting our team’s strong execution," said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. "Importantly, our net sales growth on an organic, constant currency basis included balanced contributions from both our Orthopedic and General Surgery product lines, which were in turn powered by commercial traction across our key product growth platforms: AirSeal, Buffalo Filter, and BioBrace. Our updated full year guidance reflects this strong performance in the third quarter and our latest outlook as we close out the year."

Mr. Beyer continued: "Looking ahead, our global team remains focused on executing our growth strategy to expand awareness and adoption of our key product platforms across the minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair markets. With a sharpened strategic focus on these key markets following our recent portfolio optimization activities, CONMED is better positioned to support our customers, expand our market share, and drive both long-term growth and value creation going forward."

2026 Financial Guidance

The Company is updating its full year 2026 financial guidance to reflect its third quarter performance and updated outlook for the full year. For the twelve months ended December 31, 2026, the Company now expects:

Notes to Financial Information Above

(1)

All growth rates are presented on a year-over-year basis, unless noted otherwise.

(2)

Constant currency growth, organic growth, organic constant currency growth, and adjusted EPS are non-GAAP financial measures. Reconciliations of GAAP to non-GAAP financial measures appear below.

(3)

Organic constant currency revenue excludes the sales of gastroenterology ("GI") product offerings for the three and nine months ended September 30, 2026 and 2025, and twelve months ending December 31, 2026 and 2025, related to the Company’s previously announced strategic exits as part of its portfolio optimization strategy.

(4)

Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.

(5)

"Prior financial guidance" reflects the Company’s full year 2026 financial guidance, previously updated on July 29, 2026.

Conference Call

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its third quarter 2026 results.

To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call webcast can also be accessed from the “Investors” section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

(1) Amounts reported in millions within the Sales Summary are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

(2) Organic constant currency revenue excludes the sales of gastroenterology ("GI") product offerings for the three months ended September 30, 2026 and 2025.

(1) Amounts reported in millions within the Sales Summary are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

(2) Organic constant currency revenue excludes the sales of gastroenterology ("GI") product offerings for the nine months ended September 30, 2026 and 2025.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements... (truncated)rom those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; organic sales growth; organic constant currency sales growth; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted research and development expense; adjusted operating income; adjusted interest expense; adjusted other (income)/expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on a constant currency basis, organic basis, and organic constant currency basis are non-GAAP measures. The Company analyzes net sales on a constant currency basis, organic basis, and organic constant currency basis to better measure the comparability of results between periods. Organic revenue excludes the sales of GI product offerings and organic constant currency revenue presents sales in constant currency and excludes the sales of GI product offerings. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, research and development expense, operating income, interest expense, other (income)/expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.